Nonalcoholic Fatty Liver Disease Clinical Trials 2023

What are the top hospitals conducting nonalcoholic fatty liver disease research?

When it comes to advancing research and providing hope for patients with nonalcoholic fatty liver disease (NAFLD), several hospitals are leading the way. At Massachusetts General Hospital in Boston, experts are currently conducting two active clinical trials focused on NAFLD. With a remarkable history of 24 completed trials dedicated to this condition, dating back to their first recorded trial in 2010, this renowned institution is at the forefront of NAFLD research. In Montclair, Catalina Research Institute, LLC may have only one ongoing clinical trial for NAFLD but has already made significant contributions with six previously conducted trials since initiating their first investigation in 2018.

Meanwhile, down in San Antonio's Texas Liver Institute operated under American Research Corporation umbrella also serves as an important center for NAFLD studies with its single ongoing trial complemented by twelve previous investigations since recording its maiden entry into studying such cases five years prior around 2015.Although Accel Research Sites based out of DeLand has just entered the field recently with one active clinical test regarding this condition after having initiated its very initial exploration journey merely three years away from current date approximately by2023 which brings us another re-established pioneer Velocity Clinical Research situated within Chula Vista introducing itself cautiously towards gaining expertise through starting off pertaining specifically to nonalcoholic fatty liver disease while they hold a couple more registered attempts by similar time frame commencing year2023.

These hospitals represent beacons of progress and innovation in tackling a complex and increasingly prevalent condition like NAFLD. The work being done across these institutions emphasizes the importance of understanding and finding solutions for this disease that affects millions worldwide. Through their dedication to seeking effective treatments and improving patient outcomes, they pave the way toward a future where individuals living with NAFLD can find renewed hope and better quality of life.

Which are the best cities for nonalcoholic fatty liver disease clinical trials?

When it comes to nonalcoholic fatty liver disease clinical trials, several cities have emerged as leaders in research. San Antonio, Texas is at the forefront with 6 active trials investigating interventions such as LY3849891 and BI 3006337 dose group 4. Miami, Florida follows closely behind with 3 ongoing studies focusing on treatments like LY3849891 and Efinopegdutide 4mg. La Mesa, California also plays a role with 2 active trials examining BI 3006337 dose group 4 and Efinopegdutide 4mg. Additionally, Miami Lakes, Florida and Hialeah, Florida each have 2 active trials studying Efinopegdutide in particular. These cities offer individuals living with nonalcoholic fatty liver disease access to cutting-edge clinical trials that contribute to advancements in treatment options for this condition.

Which are the top treatments for nonalcoholic fatty liver disease being explored in clinical trials?

Clinical trials are actively exploring various treatment options for nonalcoholic fatty liver disease (NAFLD). One of the top contenders is dietary intervention, which has been studied in one ongoing trial and two all-time NAFLD trials since 2015. Another promising candidate is LY3849891, currently being tested in one active clinical trial dedicated to NAFLD. This drug made its debut on the research scene in 2022 and shows potential as a therapeutic option for this condition. As researchers delve deeper into these treatments, they aim to uncover effective strategies to combat NAFLD, providing hope for patients worldwide.

What are the most recent clinical trials for nonalcoholic fatty liver disease?

Recent clinical trials for nonalcoholic fatty liver disease offer promising prospects for patients seeking effective treatments. One such study evaluated the efficacy of BI 3006337 dose group 4, a potential intervention in Phase 1 trials that became available on August 2, 2023. Additionally, efinopegdutide at a dosage of 4mg underwent Phase 2 testing and emerged as another avenue to explore in the fight against this liver condition; it became available on June 23, 2023. These ongoing investigations provide hope and pave the way towards improved management strategies for individuals affected by nonalcoholic fatty liver disease.

What nonalcoholic fatty liver disease clinical trials were recently completed?

In recent years, a multitude of clinical trials have been conducted to explore potential treatments for nonalcoholic fatty liver disease (NAFLD). Noteworthy among these are the completion of several significant trials. In March 2022 and September 2021 respectively, Altimmune, Inc. completed trials investigating ALT-801. Additionally, in August 2021, BIO89-100 was studied by 89bio, Inc., while Merck Sharp & Dohme Corp. concluded their trial on Efinopegdutide 20 mg/mL the same month. Further notable completions include Amgen's trial on AMG 609 in May 2021 and Terns, Inc.'s investigation into TERN-201 during the same period. These successful endeavors contribute to our ever-growing understanding of NAFLD treatment options and provide hope for patients affected by this condition.